Rare Disease News and Research

RSS

Gene mutation gradually causes devastating effects on cellular structure and function in Hutchinson-Gilford progeria syndrome

A mutation of the gene for lamin A protein gradually causes devastating effects on cellular structure and function in Hutchinson-Gilford progeria syndrome

29 Jun 2004

Chemical agents extracted from Caribbean sea squirt may help find cancer treatments for certain deadly tumours

European Union funding is helping to find cancer treatments for certain deadly tumours using small marine animals. European researchers are using chemical agents extracted from a type of Caribbean sea squirt, named Ecteinascidia turbinata, to treat some tumours.

11 Jun 2004

FDA approves new drug for bone marrow disease

The Food and Drug Administration (FDA) today announced the approval of Vidaza (azacitidine) injection, the first effective treatment for patients with Myelodysplastic Syndrome (MDS). The product was given Fast Track Status and a priority review.

19 May 2004

New Center for International Blood and Marrow Transplant Research

In their mission to improve transplant access and outcomes for patients, the National Marrow Donor Program® (NMDP) and the Medical College of Wisconsin’s International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry (IBMTR/ABMTR) have created the Center for International Blood and Marrow Transplant Research (CIBMTR.)

14 May 2004

New research center created by leading blood and marrow transplant organizations

11 May 2004

Scientists looking for 480 people to test experimental anthrax vaccine

Scientists in Rochester and 11 other cities around the nation are beginning tests of an experimental vaccine aimed at protecting people against anthrax, a rare disease that, like smallpox, has become more threatening with the emergence of bioterrorism.

28 Apr 2004

FDA approves new breakthrough Parkinson's drug

FDA has approved Apokyn (apomorphine) as an injectable drug for treating Parkinson's patients during episodes of "hypomobility," so-called "off periods" in which the patient becomes immobile or unable to perform activities of daily living.

21 Apr 2004

FDA approves advanced malignant melanoma drug

Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA).

14 Apr 2004

Protein kinase complex influences the outer layer of skin to control the eventual shape of the full-grown skeleton and skull

Continuing studies about an important regulatory protein kinase complex called I-kappa-B kinase (or IKK) have now shown that a subunit of IKK – IKK alpha – influences the outer layer of skin in developing mice to control the eventual shape of the full-grown skeleton and skull.

7 Apr 2004

Drug Based on Brain Chemical Could End Narcolepsy and Insomnia

Researchers at UT Southwestern Medical Center at Dallas have discovered a potentially new avenue for treating human narcolepsy, and the work may also lead to more effective ways for insomniacs to boost their wakefulness during the daytime.

22 Mar 2004